At long last, the Food and Drug Administration (FDA) has announced plans to study the safety of the drug mifepristone, better known as the “abortion pill.”
The decision comes years after President Joe Biden and his administration authorized the drug to be distributed via telehealth appointments and through the mail. Previously, any woman who sought the prescription pharmaceutical was required to see a doctor in-person.
Advocates for the abortion pill are quick to downplay some of the serious side effects of the drug.
Some of those include hemorrhage, severe infection (sepsis), and undetected ectopic pregnancy, which is a life-threatening pregnancy outside the uterus. Common side effects include heavy bleeding and blood clots, cramping, nausea, fever and dizziness.
Those advocating for easy distribution of the abortion drug point to years of data purporting to prove its “safety and effectiveness.” Tragically, they ignore the danger of what can happen when unsuspecting women recklessly and cavalierly pop pills that are designed to kill the life of preborn children.
Calling any drug whose consumption will lead to the death of a preborn baby as “safe” is delusional, but also dangerous for the mother. When you consider that for more than two decades the drug was always dispensed in-person, it’s logical that the medical oversight that process included likely minimized any spike in side effects escalating into the death of the woman taking the pill.
Yet, in their effort to normalize and expand access to abortion, Planned Parenthood dismisses concerns raised by pro-life advocates regarding the unmonitored distribution of the drug.” Planned Parenthood’s Alexis McGill, the leading abortion organization’s CEO, called the FDA’s wise review “a politically motivated farce.”
The idiom, “The pot calling the kettle black,” immediately comes to mind.
Planned Parenthood and McGill’s manic obsession with abortion is so acute that they’re willing to politicize the safety of women in order to keep the killer drugs flowing through the mail on demand.
“We already know chemical abortions kill babies and endanger women,” said Sen. Bill Cassidy (R-LA), chairman of the Senate’s health committee. “The Trump administration needs to stop dragging their feet and immediately reinstate the in-person requirement.”
It’s been reported that former FDA Commissioner Marty Makary, who was fired last month, supported the idea of a review, but was awaiting new technology to make it happen. The study will involve pouring over medical records of women who have taken the drug and then evaluating health concerns and outcomes.
According to Thursday’s Wall Street Journal, the new study has the support of the White House.
The pro-life friendly state of Louisiana is challenging the current Biden-era rules that allow mifepristone to be distributed via telemedicine, mail and pharmacies. They’re rightly arguing that current regulations undermine and outright violate their state’s ban on abortion.
Earlier this spring, the Fifth Circuit Court of Appeals agreed with Louisiana’s claim, but the Supreme Court stayed the ruling, which allowed the reckless distribution of the abortion pill to continue. The case remains under review in the Fifth Circuit and could eventually make its way back to the High Court.
The current FDA review could take up to six months, though initial findings could be issued this summer.
Please join us in praying for a thorough, honest, and critical review of the dangers of the drug and that officials will acknowledge and address the myriad of dangers associated with this deadly drug.
Daily Citizen is a news division of Focus on the Family that provides a faith-based perspective to counter the mainstream media’s anti-Christian bias.
